Edition:
United States

Navamedic ASA (NAVA.OL)

NAVA.OL on Oslo Stock Exchange

10.70NOK
18 Aug 2017
Change (% chg)

kr0.30 (+2.88%)
Prev Close
kr10.40
Open
kr10.25
Day's High
kr10.85
Day's Low
kr10.15
Volume
7,552
Avg. Vol
20,613
52-wk High
kr18.00
52-wk Low
kr9.90

Latest Key Developments (Source: Significant Developments)

Navamedic Q2 EBITDA NOK 5.5​ million
Friday, 28 Jul 2017 01:00am EDT 

July 28 (Reuters) - NAVAMEDIC ASA :Q2 REVENUE NOK 89.7 MILLION VERSUS NOK 66.7 MILLION YEAR AGO.Q2 EBITDA NOK 5.5​ MILLION VERSUS LOSS NOK 1.6 MILLION YEAR AGO.‍DISCONTINUATION OF ASPEN PARTNERSHIP IS EXPECTED TO RESULT IN A NEGATIVE IMPACT ON REVENUE AND A SHORT-TERM PRESSURE ON EBITDA.​.  Full Article

Navamedic granted European patent for Sippi base technology
Wednesday, 31 May 2017 05:00am EDT 

May 31 (Reuters) - NAVAMEDIC ASA :NAVAMEDIC ASA: GRANTED EUROPEAN PATENT FOR SIPPI® BASE TECHNOLOGY.‍HAS BEEN GRANTED A PATENT BY EUROPEAN PATENT OFFICE FOR BASE TECHNOLOGY OF SIPPI​.  Full Article

Navamedic Q1 EBITDA at NOK 3.3 Million
Wednesday, 10 May 2017 01:01am EDT 

May 10 (Reuters) - NAVAMEDIC ASA ::Q1 EBITDA NOK 3.3 MILLION VERSUS NOK 2.1 MILLION YEAR AGO.REVENUES OF NOK 78.2 MILLION IN Q1 OF 2017 (NOK 60.8 MILLION IN Q1 2016).THE DISCONTINUATION OF THE ASPEN PARTNERSHIP END Q2 IS EXPECTED TO RESULT IN A NEGATIVE IMPACT ON THE REVENUE AND A SHORT-TERM PRESSURE ON EBITDA..  Full Article

Navamedic signs deal with Orexigen Therapeutics for Nordic launch of Mysimba
Tuesday, 2 May 2017 03:00am EDT 

May 2 (Reuters) - NAVAMEDIC ASA :NAVAMEDIC ASA: ENTERS INTO PARTNERSHIP AGREEMENT WITH OREXIGEN THERAPEUTICS FOR NORDIC LAUNCH OF MYSIMBA®.HAS ENTERED INTO A FIVE-YEAR AGREEMENT WITH OREXIGEN THERAPEUTICS IRELAND, LTD., FOR NORDIC MARKETING AND DISTRIBUTION OF MYSIMBA®, A PRESCRIPTION PHARMACEUTICAL..NAVAMEDIC EXPECTS TO BEGIN MARKETING PRODUCT DURING Q4 2017 FOR AN INITIAL PERIOD OF FIVE YEARS, RENEWABLE FOR AN ADDITIONAL FIVE-YEAR PERIOD, ACCORDING TO TERMS OF AGREEMENT.  Full Article

Navamedic enters into distribution agreement for Sippi in Italy
Friday, 7 Apr 2017 02:00am EDT 

NAVAMEDIC ASA : NAVAMEDIC ASA: ENTERS INTO DISTRIBUTION AGREEMENT FOR SIPPI® IN ITALY .HAS ENTERED AN AGREEMENT WITH ITALY- BASED SIM ITALIA SRL (SIM ITALIA), A LEADING DISTRIBUTOR OF STERILE MEDICAL DEVICES, FOR LAUNCH OF SIPPI® IN ITALY.  Full Article

Navamedic: Sippcoat granted European patent
Friday, 20 Jan 2017 02:22am EST 

Navamedic Asa : European Patent Office has granted a patent for Sippcoat to be used in any urine handling system to help prevent bacteria migration .Says this yields major licensing opportunities and hence an additional multi-million NOK market potential for Navamedic.  Full Article

Navamedic appoints Toril Marie Ås new CFO
Tuesday, 23 Aug 2016 04:18am EDT 

Navamedic ASA : Appoints new CFO .Toril Marie Ås has been Navamedic's interim CFO since February 1, 2016.  Full Article

Navamedic Q2 EBITDA swings to loss of NOK 1.6 million
Thursday, 18 Aug 2016 01:01am EDT 

Navamedic ASA : Q2 revenue 66.7 million Norwegian crowns ($8.15 million)versus 59.6 million crowns year ago . Q2 EBITDA loss 1.6 million crowns versus profit 3.5 million crowns year ago .Distribution of angina prevention medicine, Imdur, expected to contribute annual future revenue of 70 million-100 million crowns; initial revenue expected during H2 2016.  Full Article

Navamedic ends partnership with Aspen Pharma in 2017
Tuesday, 5 Jul 2016 03:51am EDT 

Navamedic ASA : Ends partnership with Aspen Pharma in 2017 . Partnership termination is in line with Navamedic's June 13, 2016 announcement on strategic partnership with TopRidge Pharma Limited .Current contract expires mid-May 2017.  Full Article

Navamedic: New patent for Sippi line extension
Wednesday, 15 Jun 2016 02:09am EDT 

Navamedic ASA : Announces new patent for Sippi line extension .Swedish Patent and Registration Office has granted new patent pertaining to Sippcoat.  Full Article

BRIEF-Navamedic Q2 EBITDA NOK 5.5​ million

* Q2 REVENUE NOK 89.7 MILLION VERSUS NOK 66.7 MILLION YEAR AGO